Niagen Bioscience, Inc. — Director's Dealing 2020

Dec 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2020-12-10

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-10	Common Stock	M	41667	$4.62	Acquired	262168	Direct
2020-12-10	Common Stock	S	37829	$5.19	Disposed	224339	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-10	Employee Stock Options (right to buy)	$4.62	M	41667	Disposed	2021-05-10	Common Stock (41667)	Direct

Footnotes

F1: The shares were sold to cover the cost of the exercise of the options which were scheduled to expire on May 10, 2021.

F2: The weighted average sale price for the transaction reported was $5.19, and the range of prices were between $5.15 and $5.25. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.